Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Telomir Pharmaceuticals, Inc. ( (TELO) ).
On August 28, 2025, Telomir Pharmaceuticals, Inc. successfully completed the sale of 1,550,000 shares of its common stock to institutional investors at an average price of $1.87 per share, generating gross proceeds of approximately $2.9 million. This transaction, facilitated through Rodman & Renshaw via the StockBlock platform, was conducted without the inclusion of any warrants and reflects a premium to the prior day’s closing price, potentially indicating strong investor confidence and positively impacting the company’s financial position.
The most recent analyst rating on (TELO) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Telomir Pharmaceuticals, Inc. stock, see the TELO Stock Forecast page.
More about Telomir Pharmaceuticals, Inc.
Average Trading Volume: 4,527,206
Technical Sentiment Signal: Sell
Current Market Cap: $38.74M
Find detailed analytics on TELO stock on TipRanks’ Stock Analysis page.